Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription Articles published in Lancet Retrieve available abstracts of 39 articles: HTML format

Single Articles

September 2025
1. MATHIEU C, Wych J, Hendriks AEJ, Van Ryckeghem L, et al
   Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial.
   Lancet. 2025 Sep 18:S0140-6736(25)01674-5. doi: 10.1016/S0140-6736(25)01674.
   PubMed     Abstract available
   
   
   March 2025
2. BANERJEE SS, Sahai S, Chate GP
   Guillain-Barre syndrome outbreak in Pune: a health emergency.
   Lancet. 2025 Mar 21:S0140-6736(25)00414-3. doi: 10.1016/S0140-6736(25)00414.
   PubMed    
   
   
   
3. LATEEF S
   India faces major Guillain-Barre syndrome epidemic.
   Lancet. 2025;405:769.
   PubMed    
   
   
   January 2025
4. ACHARYA NR, Ramanan AV, Coyne AB, Dudum KL, et al
   Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
   Lancet. 2025;405:303-313.
   PubMed     Abstract available
   
   
   
5. BENHADOU F, Cogan E
   Targeting IFNbeta in dermatomyositis.
   Lancet. 2025;405:99-101.
   PubMed    
   
   
   
6. FIORENTINO D, Mangold AR, Werth VP, Christopher-Stine L, et al
   Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
   Lancet. 2025;405:137-146.
   PubMed     Abstract available
   
   
   November 2024
7. DE FREMONT GM, Lenfant T, Le Guern V, Costedoat-Chalumeau N, et al
   Therapies for systemic lupus erythematosus.
   Lancet. 2024;404:2163.
   PubMed    
   
   
   
8. MATUCHANSKY C
   Therapies for systemic lupus erythematosus.
   Lancet. 2024;404:2163.
   PubMed    
   
   
   
9. HOI A, Igel T, Mok CC, Arnaud L, et al
   Therapies for systemic lupus erythematosus - Authors' reply.
   Lancet. 2024;404:2163-2164.
   PubMed    
   
   
   
10. XU Q
    Therapies for systemic lupus erythematosus.
    Lancet. 2024;404:2162.
    PubMed    
    
    
    
11. PABST T, Maurer B
    Therapies for systemic lupus erythematosus.
    Lancet. 2024;404:2162.
    PubMed    
    
    
    
12. HAGEN M, Muller F, Wirsching A, Kharboutli S, et al
    Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells.
    Lancet. 2024;404:2158-2160.
    PubMed    
    
    
    September 2024
13. LOVE KM, Brown SA
    The promise of once-weekly insulins for type 1 diabetes: update on progress.
    Lancet. 2024;404:1081-1083.
    PubMed    
    
    
    
14. BERGENSTAL RM, Weinstock RS, Mathieu C, Onishi Y, et al
    Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.
    Lancet. 2024;404:1132-1142.
    PubMed     Abstract available
    
    
    August 2024
15. AL-SAMKARI H, B Bussel J, Miyakawa Y, Broome CM, et al
    Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply.
    Lancet. 2024;404:434.
    PubMed    
    
    
    
16. JACOBS JW, Booth GS, Stephens LD, Tormey CA, et al
    Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.
    Lancet. 2024;404:433.
    PubMed    
    
    
    
17. MA RW, Liu K, Xie J
    Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial.
    Lancet. 2024;404:433-434.
    PubMed    
    
    
    July 2024
18. SCHETT G, Mackensen A, Mougiakakos D
    CAR T-cell perspectives in lupus - Authors' reply.
    Lancet. 2024;404:336-337.
    PubMed    
    
    
    
19. GREMESE E, Bruno D, Ferraccioli G
    CAR T-cell perspectives in lupus.
    Lancet. 2024;404:336.
    PubMed    
    
    
    June 2024
20. LAFAYETTE R, Kristensen J, Stone A, Barratt J, et al
    Targeted release of budesonide in primary IgA nephropathy - Authors' reply.
    Lancet. 2024;403:2786.
    PubMed    
    
    
    
21. ZOU Y, Du X, Zou J
    Targeted release of budesonide in primary IgA nephropathy.
    Lancet. 2024;403:2785-2786.
    PubMed    
    
    
    
22. HU Y, Zhang Y
    Targeted release of budesonide in primary IgA nephropathy.
    Lancet. 2024;403:2785.
    PubMed    
    
    
    
23. SAKUMA I, Ishibashi R, Matsue K, Vatner DF, et al
    Primary adrenal insufficiency due to lymphomatoid granulomatosis in a 32-year-old man.
    Lancet. 2024;403:e33.
    PubMed    
    
    
    April 2024
24. HOI A, Igel T, Mok CC, Arnaud L, et al
    Systemic lupus erythematosus.
    Lancet. 2024 Apr 17:S0140-6736(24)00398-2. doi: 10.1016/S0140-6736(24)00398.
    PubMed     Abstract available
    
    
    
25. KRICKAU T, Naumann-Bartsch N, Aigner M, Kharboutli S, et al
    CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis.
    Lancet. 2024 Apr 17:S0140-6736(24)00424-0. doi: 10.1016/S0140-6736(24)00424.
    PubMed    
    
    
    February 2024
26. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
    Diagnosis and management of ANCA-associated vasculitis.
    Lancet. 2024;403:683-698.
    PubMed     Abstract available
    
    
    
27. VAN DER HELM-VAN MIL AHM
    Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis.
    Lancet. 2024 Feb 14:S0140-6736(24)00055-2. doi: 10.1016/S0140-6736(24)00055.
    PubMed    
    
    
    January 2024
28. WEST EE, Woodruff T, Fremeaux-Bacchi V, Kemper C, et al
    Complement in human disease: approved and up-and-coming therapeutics.
    Lancet. 2024;403:392-405.
    PubMed     Abstract available
    
    
    
29. CHAKER L, Cooper DS, Walsh JP, Peeters RP, et al
    Hyperthyroidism.
    Lancet. 2024 Jan 23:S0140-6736(23)02016-0. doi: 10.1016/S0140-6736(23)02016.
    PubMed     Abstract available
    
    
    November 2023
30. JAKIMOVSKI D, Bittner S, Zivadinov R, Morrow SA, et al
    Multiple sclerosis.
    Lancet. 2023 Nov 7:S0140-6736(23)01473-3. doi: 10.1016/S0140-6736(23)01473.
    PubMed     Abstract available
    
    
    
31. REICH HN, Barbour SJ
    PROTECTing the kidneys in IgA nephropathy.
    Lancet. 2023 Nov 3:S0140-6736(23)02418-2. doi: 10.1016/S0140-6736(23)02418.
    PubMed    
    
    
    
32. ROVIN BH, Barratt J, Heerspink HJL, Alpers CE, et al
    Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Lancet. 2023 Nov 2:S0140-6736(23)02302-4. doi: 10.1016/S0140-6736(23)02302.
    PubMed     Abstract available
    
    
    
33. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    PubMed     Abstract available
    
    
    October 2023
34. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    PubMed     Abstract available
    
    
    
35. RUSSELL-JONES D, Babazono T, Cailleteau R, Engberg S, et al
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Lancet. 2023 Oct 17:S0140-6736(23)02179-7. doi: 10.1016/S0140-6736(23)02179.
    PubMed     Abstract available
    
    
    
36. SHAH AS, Wolf RM
    Weekly insulin: a paradigm shift in type 1 diabetes therapy.
    Lancet. 2023 Oct 17:S0140-6736(23)02227-4. doi: 10.1016/S0140-6736(23)02227.
    PubMed    
    
    
    September 2023
37. BROOME CM, McDonald V, Miyakawa Y, Carpenedo M, et al
    Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2023 Sep 28:S0140-6736(23)01460-5. doi: 10.1016/S0140-6736(23)01460.
    PubMed     Abstract available
    
    
    
38. MAHAMAD S, Arnold DM
    Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.
    Lancet. 2023 Sep 28:S0140-6736(23)01836-6. doi: 10.1016/S0140-6736(23)01836.
    PubMed    
    
    
    
39. SCHETT G, Mackensen A, Mougiakakos D
    CAR T-cell therapy in autoimmune diseases.
    Lancet. 2023 Sep 22:S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.